The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.
Under the new framework, Indian tariffs on EU pharmaceutical exports currently at 11 percent and chemicals currently up to 22% will drop to 0 percent for almost all products. Similarly, 90 percent of medical and surgical equipment will see tariffs fall from 27.5 percent to zero.
EU will reciprocate by cutting tariffs on 97.5 percent of India’s chemical exports from 12.8 percent to zero, a move expected to catalyze growth in bulk and specialty chemicals. Indian pharmaceuticals already enjoy zero duty entry into the EU, but the deal would offer preferential access to the EU pharma market and improved competitiveness for medical devices.
The free flow of pharmaceutical, chemicals and machinery will help India to plug into global supply chain and offers Europe an alternative supply base and market..
EU also clarified that all imports from India to the EU will continue to be subject to the EU’s strict health and product safety rules, with no exception.
On the contentious intellectual property (IP) rights, EU said the agreement also provides a high level of protection and enforcement of IP rights, including with respect to copyright, trademarks, designs, protection of trade secrets and undisclosed information, plant varieties.
Reference:
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
N,N′-Dimethylethylenediamine (DMEDA) is an organic chemical compound belonging to the diamine family. It contains two nitrogen atoms, each bearing a methyl group, connected by a two-carbon chain.
Global shipping costs have climbed to $4,000–$4,500 in October from $2,000–$2,500 in February 2026. Freight rates, which had eased through much of 2025 and early 2026 as the demand-supply balance improved, have rebounded sharply in recent months. The increase has brought shipping costs back into focus for businesses dependent on international cargo movement.
The U.S. Food and Drug Administration (FDA) has finalized guidance outlining how manufacturers should report post-approval manufacturing changes for biosimilar and interchangeable biosimilar products. The guidance provides greater regulatory clarity on changes involving production processes, manufacturing sites, analytical methods, raw materials, and process controls. It aims to ensure product quality while reducing unnecessary regulatory burden.